<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Polypoidal choroidal vasculopathy &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/polypoidal-choroidal-vasculopathy/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Wed, 03 Jun 2026 04:05:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Polypoidal choroidal vasculopathy &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study on the Effects of Faricimab for Caucasian Patients with Polypoidal Choroidal Vasculopathy</title>
		<link>https://clinicaltrials.eu/trial/study-on-the-effects-of-faricimab-for-caucasian-patients-with-polypoidal-choroidal-vasculopathy/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:06:01 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-the-effects-of-faricimab-for-caucasian-patients-with-polypoidal-choroidal-vasculopathy/</guid>

					<description><![CDATA[This clinical trial is focused on studying a condition called polypoidal choroidal vasculopathy, which affects the eyes and can lead to vision problems. The study will use a treatment called faricimab, also known by its code name RO6867461. Faricimab is a solution for injection that is administered directly into the eye. The purpose of the [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial is focused on studying a condition called <i>polypoidal choroidal vasculopathy</i>, which affects the eyes and can lead to vision problems. The study will use a treatment called <i>faricimab</i>, also known by its code name <i>RO6867461</i>. Faricimab is a solution for injection that is administered directly into the eye. The purpose of the study is to evaluate how effective and safe faricimab is in improving vision in patients with this eye condition.</p>
<p>Participants in the study will receive regular injections of faricimab over a period of time. The study will monitor changes in vision, specifically looking at improvements in the ability to see clearly, which is measured by a test called <i>Best Corrected Visual Acuity</i> (BCVA). The study will also observe any changes in the eye&#8217;s condition, such as the presence of fluid or changes in the thickness of the retina, which is the light-sensitive layer at the back of the eye.</p>
<p>The study will take place over several years, with regular check-ups to assess the effects of the treatment. Participants will be monitored for any side effects, both related to the eye and overall health. The goal is to determine if faricimab can help maintain or improve vision in people with polypoidal choroidal vasculopathy, providing valuable information for future treatments of this condition.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
